Lybaert Willem
AZ Nikolaas, Sint-Niklaas, Belgium.
Case Rep Oncol. 2014 Jan 16;7(1):43-6. doi: 10.1159/000358124. eCollection 2014 Jan.
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer. The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction. Here, we report a case of recurrent intestinal obstruction in a patient with adenocarcinoma. Although the obstruction was resolved after 3 days of treatment with octreotide, new episodes of obstruction occurred, resulting in a delay of the chemotherapy treatment. After 3 episodes of obstruction, we initiated treatment with a longer-acting somatostatin analogue, lanreotide Autogel® 120 mg, administered once every 4 weeks. The treatment with lanreotide Autogel is being continued, allowing for continuation of the chemotherapy without further episodes of intestinal subocclusion or obstruction. Until November 2013, the patient received eighteen 4-weekly injections of lanreotide Autogel and did not report side effects. This case report demonstrates the successful treatment of intestinal obstruction with lanreotide Autogel in a patient with adenocarcinoma.
肠梗阻是晚期腹部或盆腔癌症患者的常见并发症。合成生长抑素类似物奥曲肽可帮助缓解无法手术治疗的肠梗阻患者的恶心、呕吐和疼痛。在此，我们报告一例腺癌患者复发性肠梗阻的病例。尽管使用奥曲肽治疗3天后梗阻得到缓解，但新的梗阻发作仍有发生，导致化疗延迟。在经历3次梗阻发作后，我们开始使用长效生长抑素类似物兰瑞肽缓释凝胶120mg进行治疗，每4周给药一次。兰瑞肽缓释凝胶的治疗仍在继续，使化疗得以继续进行，未再出现肠道不完全梗阻或梗阻发作。截至2013年11月，该患者接受了18次每4周一次的兰瑞肽缓释凝胶注射，未报告有副作用。本病例报告证明了兰瑞肽缓释凝胶成功治疗了一名腺癌患者的肠梗阻。
